赖氨酸特异性去甲基化酶KDM1A在慢性淋巴细胞白血病中的致癌作用及靶向特性
在慢性淋巴细胞白血病(CLL)中,表观遗传改变被认为是驱动疾病演化和生物学亚群的核心因素。本研究鉴定出KDM1A与TCL1A蛋白相互作用并催化活性增加,KDM1A在恶性B细胞中上调,其高表达与侵袭性疾病特征和不良临床结局相关;基因敲低Kdm1a可减轻Eμ-TCL1A小鼠的白血病负荷并延长生存,药理学抑制KDM1A显示出明显的抗B细胞白血病协同作用。
要点
- KDM1A在CLL恶性B细胞中上调,与TCL1A相互作用并催化活性增加。
- KDM1A高表达及关联基因特征与侵袭性疾病特征和不良临床结局相关。
- 基因敲低Kdm1a减轻Eμ-TCL1A小鼠白血病负荷并延长生存,伴随p53和促凋亡通路上调。
核心结论
- 本研究确立了KDM1A在CLL中的致病作用及效应网络,通过肿瘤细胞内在机制及其对微环境细胞的影响。
- 数据为进一步研究CLL中治疗性靶向KDM1A提供了依据。
研究设计与样本
- 研究在CLL中鉴定与TCL1A相互作用的效应分子,使用Eμ-TCL1A小鼠模型进行基因敲低实验,并整合RNA测序和染色质免疫沉淀测序分析。
- 利用大型前瞻性CLL试验队列分析KDM1A表达与临床结局的关联。
主要发现
- KDM1A在恶性B细胞中上调,与TCL1A蛋白在B细胞中相互作用并伴随KDM1A催化活性增加。
- KDM1A高表达及相关基因表达特征与侵袭性疾病特征和不良临床结局相关。
- Eμ-TCL1A小鼠中基因敲低Kdm1a减轻白血病负荷并延长动物生存,伴随p53和促凋亡通路上调。
- 基因敲除KDM1A还影响微环境成分(T细胞、基质细胞和单核细胞),显著降低其支持CLL细胞存活和增殖的能力。
- 药理学抑制KDM1A改变H3K4/9靶标甲基化并显示明显的抗B细胞白血病协同作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic lymphocytic leukemia (CLL), epigenetic alterations are considered to centrally shape the transcriptional signatures that drive disease evolution and underlie its biological and clinical subsets. Characterizations of epigenetic regulators, particularly histone-modifying enzymes, are very rudimentary in CLL. In efforts to establish effectors of the CLL-associated oncogene T-cell leukemia 1A (TCL1A), we identified here the lysine-specific histone demethylase KDM1A to interact with the TCL1A protein in B cells in conjunction with an increased catalytic activity of KDM1A. We demonstrate that KDM1A is upregulated in malignant B cells. Elevated KDM1A and associated gene expression signatures correlated with aggressive disease features and adverse clinical outcomes in a large prospective CLL trial cohort. Genetic Kdm1a knockdown in Eμ-TCL1A mice reduced leukemic burden and prolonged animal survival, accompanied by upregulated p53 and proapoptotic pathways. Genetic KDM1A depletion also affected milieu components (T, stromal, and monocytic cells), resulting in significant reductions in their capacity to support CLL-cell survival and proliferation. Integrated analyses of differential global transcriptomes (RNA sequencing) and H3K4me3 marks (chromatin immunoprecipitation sequencing) in Eμ-TCL1A vs iKdm1aKD;Eμ-TCL1A mice (confirmed in human CLL) implicate KDM1A as an oncogenic transcriptional repressor in CLL which alters histone methylation patterns with pronounced effects on defined cell death and motility pathways. Finally, pharmacologic KDM1A inhibition altered H3K4/9 target methylation and revealed marked anti-B-cell leukemic synergisms. Overall, we established the pathogenic role and effector networks of KDM1A in CLL via tumor-cell intrinsic mechanisms and its impacts in cells of the microenvironment. Our data also provide rationales to further investigate therapeutic KDM1A targeting in CLL.
引用
- Jiang Q, Stachelscheid J, Bloehdorn J, et al. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia. Blood. 2023. PMID: 37023372. doi:10.1182/blood.2022017230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。